Diese Informationen dienen ausschließlich zu Bildungszwecken. Konsultieren Sie stets einen Angehörigen der Gesundheitsberufe. Mehr erfahren

Dibasic Sodium Phosphate, Monobasic Potassium Phosphate And Monobasic Sodium Phosphate

Prescription

Handelsnamen: Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate

Darreichungsform
Tablet
Applikationsweg
ORAL

About This Medication

DESCRIPTION Each tablet contains 852 mg dibasic sodium phosphate anhydrous, 155 mg monobasic potassium phosphate, and 130 mg monobasic sodium phosphate monohydrate. Each tablet yields approximately 250 mg of phosphorus, 298 mg of sodium (13.0 mEq) and 45 mg of potassium (1 .1 mEq).

Wirkstoffe

Wirkstoff Stärke
Potassium Phosphate, Monobasic -
Sodium Phosphate, Dibasic, Anhydrous -
Sodium Phosphate, Monobasic, Monohydrate -

Indikationen und Anwendung

INDICATIONS AND USAGE PHOSPHA 250 TM NEUTRAL increases urinary phosphate and pyrophosphate. As a phosphorus supplement, each tablet supplies 25% of the U.S. Recommended Daily Allowance (U.S. RDA) of phosphorus for adults and children over 4 years of age.

Dosierung und Verabreichung

DOSAGE AND ADMINISTRATION PHOSPHA 250 TM NEUTRAL tablets should be taken with a full glass of water, with meals and at bedtime. Adults: One or two tablets, four times daily; Pediatric patients over 4 years of age: One tablet four times daily. Pediatric Patients under 4 years of age: Use only as directed by physician.

Side Effects Overview

ADVERSE REACTIONS: Gastrointestinal upset (diarrhea, nausea, stomach pain, and vomiting) may occur with phosphate therapy. Also, bone and joint pain (possible phosphate-induced osteomalacia) could occur. The following adverse effects may be observed (primarily from sodium or potassium): headaches; dizziness; mental confusion; seizures; weakness or heaviness of legs; unusual tiredness or weakness; muscle cramps; numbness, tingling, pain or weakness of hands or feet; numbness or tingling around lips; fast or irregular heartbeat; shortness of breath or troubled breathing; swelling of feet or lower legs; unusual weight gain; low urine output; unusual thirst. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc., at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Kontraindikationen

Frequently Asked Questions

INDICATIONS AND USAGE PHOSPHA 250 TM NEUTRAL increases urinary phosphate and pyrophosphate. As a phosphorus supplement, each tablet supplies 25% of the U.S. Recommended Daily Allowance (U.S. RDA) of phosphorus for adults and children over 4 years of age.

DOSAGE AND ADMINISTRATION PHOSPHA 250 TM NEUTRAL tablets should be taken with a full glass of water, with meals and at bedtime. Adults: One or two tablets, four times daily; Pediatric patients over 4 years of age: One tablet four times daily. Pediatric Patients under 4 years of age: Use only as directed by physician.

CONTRAINDICATIONS This product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Dibasic Sodium Phosphate, Monobasic Potassium Phosphate And Monobasic Sodium Phosphate is a prescription medication. You will need a valid prescription from a licensed healthcare provider.

Similar Tablet Products

Browse all Tablet products →

References & Data Sources

Medizinischer Haftungsausschluss

Die Informationen auf dieser Seite dienen ausschließlich zu Bildungszwecken und sollten nicht als Ersatz für professionellen ärztlichen Rat, Diagnose oder Behandlung verwendet werden.

Wenden Sie sich bei Fragen zu einem medizinischen Zustand oder einem Arzneimittel stets an Ihren Arzt oder einen anderen qualifizierten Angehörigen der Gesundheitsberufe.

Datenquellen: DailyMed (NLM), openFDA, MFDS

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.